肥胖对接受生物制剂治疗的炎症性肠病患者住院、手术及严重感染风险的影响:CA-IBD队列研究
在加州5个医疗系统基于电子健康记录的多中心队列中,纳入2010年1月1日至2017年6月30日新使用生物制剂的3038例成人炎症性肠病患者,按世界卫生组织标准分为正常体重、超重和肥胖。与正常体重相比,肥胖与住院、炎症性肠病相关手术或严重感染风险增加无关。
要点
- 肥胖与住院风险无关:校正后风险比0.90(95%CI 0.72-1.13)。
- 肥胖与炎症性肠病相关手术风险无关:校正后风险比0.62(95%CI 0.31-1.22)。
- 肥胖与严重感染风险无关:校正后风险比1.11(95%CI 0.73-1.71)。
核心结论
- 在接受生物制剂治疗的多中心电子健康记录队列的炎症性肠病患者中,肥胖与住院、手术或严重感染风险增加无关。
研究设计与样本
- 研究为基于电子健康记录的多中心队列(CA-IBD),纳入2010年1月1日至2017年6月30日来自加州5个医疗系统新使用生物制剂的成人炎症性肠病患者。
- 共纳入3038例接受生物制剂治疗的患者,其中69%为克罗恩病,76%使用肿瘤坏死因子拮抗剂。
- 按世界卫生组织标准将患者分为正常体重指数、超重和肥胖,采用Cox比例风险分析校正基线人口学、疾病和治疗特征。
主要发现
- 28.2%(n=858)为超重,13.7%(n=416)为肥胖。
- 肥胖与住院风险无关:校正后风险比0.90(95%CI 0.72-1.13)。
- 肥胖与炎症性肠病相关手术风险无关:校正后风险比0.62(95%CI 0.31-1.22)。
- 肥胖与严重感染风险无关:校正后风险比1.11(95%CI 0.73-1.71)。
- 按疾病表型(克罗恩病 vs 溃疡性结肠炎)和索引生物制剂(肿瘤坏死因子拮抗剂 vs 非肿瘤坏死因子拮抗剂)分层分析,结果相似。
局限性
- 需要进一步研究内脏肥胖对患者报告结局和内镜结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Obesity is variably associated with treatment response in biologic-treated patients with inflammatory bowel diseases (IBD). We evaluated the association between obesity and risk of hospitalization, surgery, or serious infections in patients with IBD in new users of biologic agents in a large, multicenter, electronic health record (EHR)-based cohort (CA-IBD). METHODS: We created an EHR-based cohort of adult patients with IBD who were new users of biologic agents (tumor necrosis factor [TNF-α] antagonists, ustekinumab, and vedolizumab) between January 1, 2010, and June 30, 2017, from 5 health systems in California. Patients were classified as those with normal body mass index (BMI), overweight, or obese based on the World Health Organization classification. We compared the risk of all-cause hospitalization, IBD-related surgery, or serious infections among patients with obesity vs those overweight vs those with normal BMI, using Cox proportional hazard analyses, adjusting for baseline demographic, disease, and treatment characteristics. RESULTS: Of 3,038 biologic-treated patients with IBD (69% with Crohn's disease and 76% on TNF-α antagonists), 28.2% (n = 858) were overweight, and 13.7% (n = 416) were obese. On a follow-up after biologic initiation, obesity was not associated with an increased risk of hospitalization (adjusted hazard ratio [aHR] vs normal BMI, 0.90; [95% confidence interval, 0.72-1.13]); IBD-related surgery (aHR, 0.62 [0.31-1.22]); or serious infection (aHR, 1.11 [0.73-1.71]). Similar results were observed on stratified analysis by disease phenotype (Crohn's disease vs ulcerative colitis) and index biologic therapy (TNF-α antagonists vs non-TNF-α antagonists). DISCUSSION: In a multicenter, EHR-based cohort of biologic-treated patients with IBD, obesity was not associated with hospitalization, surgery, or serious infections. Further studies examining the effect of visceral obesity on patient-reported and endoscopic outcomes are needed.
引用
- Gu P, Luo J, Kim J, et al. Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study. Am J Gastroenterol. 2022. PMID: 35973139. doi:10.14309/ajg.0000000000001855
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。